ASCO in Action

ASCO in Action provides the latest news and analysis related to critical policy issues affecting the cancer community, updates on the Association for Clinical Oncology’s ongoing advocacy efforts, and opportunities for members and others in the cancer care community to take action.

To sign up for advocacy alerts, log in to ASCO.org with your member or guest account, and visit the subscription center available under your account profile.

Tune in to the ASCO in Action podcast series for analysis and commentary on cancer policy and practice issues. The podcast is available through iTunes or Google Play.

Showing results for FDA

May 10, 2022

The Provider Relief Fund (PRF) Request to Report Late Due to Extenuating Circumstances process is for providers who were required to report in an applicable reporting period, but extenuating circumstances prevented them from doing so by the required deadline. PRF Period 2 (when payment was received) covered July 1, 2020, through December 31, 2020, with an associated reporting period (RP2) of January 1, 2022, to March 31, 2022. The deadline to request to report late for RP2 is Friday, May 13, 2022, at 11:59 p.m. ET.

May 10, 2022

Bipartisan leaders of the House Energy and Commerce Committee introduced a comprehensive legislative package to reauthorize the Food and Drug Administration (FDA) user fee agreements. The package included provisions to strengthen the accelerated approval process and increase diversity of clinical trials.

May 5, 2022

The Food and Drug Administration (FDA) recently announced two proposed rules.

April 6, 2022

On April 5, 2022, the Food and Drug Administration granted accelerated approval to alpelisib (Vijoice, Novartis Pharmaceuticals) for adult and pediatric patients two years of age and older with severe manifestations of PIK3CA-related overgrowth spectrum (PROS) who require systemic therapy.

March 24, 2022

On March 23, 2022, the Food and Drug Administration approved Pluvicto (lutetium Lu 177 vipivotide tetraxetan, Advanced Accelerator Applications USA, Inc., a Novartis company) for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy. 

March 21, 2022

On March 21, 2022, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck), as a single agent, for patients with advanced endometrial carcinoma that is microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR), as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and who are not candidates for curative surgery or radiation.

March 18, 2022

On March 18, 2022, the Food and Drug Administration approved nivolumab and relatlimab-rmbw (Opdualag, Bristol-Myers Squibb Company) for adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma. Opdualag is a fixed-dose combination of the LAG-3-blocking antibody relatlimab and the programmed death receptor-1 blocking antibody nivolumab.

March 17, 2022

Congress is considering several cancer policy priorities this week, including the PREVENT Pandemics Act, Cures 2.0, and legislation to authorize ARPA-H.

March 17, 2022

On March 17, the American Society of Clinical Oncology (ASCO) is hosting a meeting with key research stakeholders to discuss possible solutions and calls-to-action to optimize cancer clinical trials and facilitate routine patient access to trials closer to where they live.

March 15, 2022

The U.S. Food and Drug Administration and the American Society of Clinical Oncology are holding a free virtual workshop, May 3 - 5, on dose optimization for anticancer drug treatment. This timely workshop will bring together thought leaders from academia, industry, regulatory agencies, and patient groups to discuss challenges and opportunities to improve dose selection for patients.

March 11, 2022

The Fiscal Year 2022 omnibus funding bill provides $45 billion for the National Institutes of Health (NIH), including $6.9 billion for the NCI. The Association for Clinical Oncology (ASCO) commends Congress for their enthusiastic, bipartisan support for continued investment in biomedical research.

March 11, 2022

On March 11, 2022, the Food and Drug Administration approved olaparib (Lynparza, AstraZeneca Pharmaceuticals, LP) for the adjuvant treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) human epidermal growth factor receptor 2 (HER2)-negative high-risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy. Patients must be selected for therapy based on an FDA-approved companion diagnostic for olaparib.

March 8, 2022

The College of American Pathologists (CAP) and the American Society of Clinical Oncology (ASCO) hosted a virtual Immune Checkpoint Inhibition (ICI) Predictive Factor Summit to bring together stakeholders from the U.S. Food and Drug Administration (FDA), Centers for Medicare and Medicaid Services (CMS), National Institutes of Health (NIH), health insurance organizations, pharmaceutical companies, in vitro diagnostics manufacturers, and patient advocate organizations.

March 7, 2022

On March 4, 2022, the Food and Drug Administration approved nivolumab (Opdivo, Bristol-Myers Squibb Company) with platinum-doublet chemotherapy for adult patients with resectable non-small cell lung cancer (NSCLC) in the neoadjuvant setting.

March 1, 2022

On February 28, 2022, the Food and Drug Administration approved ciltacabtagene autoleucel (CARVYKTI, Janssen Biotech, Inc.) for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including a proteasome inhibitor (PI), an immunomodulatory agent (IMiD), and an anti-CD38 monoclonal antibody.

Pages